参考文献:1.International Classification of Sleep Disorders (2014) Darien, Ill.: American Academy of Sleep Medicine 2.Dauvilliers Y, Billiard M, Montplaisir J (2003) Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 114:2000–2017CrossRef PubMed 3.Overeem S, Mignot E, van Dijk JG, Lammers GJ (2001) Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 18:78–105CrossRef PubMed 4.Thannickal TC, Moore RY, Nienhuis R et al (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469–474CrossRef PubMed 5.Mignot E, Lammers GJ, Ripley B et al (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59:1553–1562CrossRef PubMed 6.Kornum BR, Faraco J, Mignot E (2011) Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Curr Opin Neurobiol 21(6):897–903CrossRef PubMed 7.Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O (2014) Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 13(6):600–613CrossRef PubMed 8.Kallweit U, Hidalgo H, Engel A, Baumann CR, Bassetti CL, Dahmen N (2012) Post H1N1 vaccination narcolepsy-cataplexy with decreased CSF beta-amyloid. Sleep Med 13(3):323CrossRef PubMed 9.Liguori C, Placidi F, Albanese M et al (2014) CSF beta-amyloid are altered in narcolepsy: a link with the inflammatory hypothesis? Sleep Res 23(4):420–424CrossRef 10.Heier MS, Skinningsrud A, Paus E, Gautvik KM (2014) Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy. Sleep Med 15(6):614–618CrossRef PubMed 11.Dauvilliers YA, Lehmann S, Jaussent I, Gabelle A (2014) Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy. Front Aging Neurosci 6:119CrossRef PubMed PubMedCentral 12.Liguori C, Placidi F, Izzi F et al (2014) May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy? Sleep Med 15(11):1424CrossRef PubMed 13.Sancesario GM, Esposito Z, Nuccetelli M et al (2010) Abeta1-42 detection in CSF of Alzheimer’s disease is influenced by temperature: indication of reversible Abeta1-42 aggregation? Exp Neurol 223(2):371–376CrossRef PubMed 14.Liguori C, Romigi A, Mercuri NB et al (2014) Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. J Neurol 261(9):1832–1836CrossRef PubMed 15.Fontana A, Gast H, Reith W, Recher M, Birchler T, Bassetti CL (2010) Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain 133:1300–1311CrossRef PubMed 16.Miyagawa T, Miyadera H, Tanaka S et al (2011) Abnormally low serum acylcarnitine levels in narcolepsy patients. Sleep 34:349–353PubMed PubMedCentral 17.Miyagawa T, Kawamura H, Obuchi M et al (2013) Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PLoS One 8:e53707CrossRef PubMed PubMedCentral 18.Romigi A, Liguori C, Izzi F et al (2015) Oral l-carnitine as treatment for narcolepsy without cataplexy during pregnancy: a case report. J Neurol Sci 348(1–2):282–283CrossRef PubMed 19.Liguori C, Dinallo V, Pieri M, et al. (2015) MicroRNA expression is dysregulated in narcolepsy: a new evidence? Sleep Med 16(8):1027–1028 20.Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci 28(33):8354–8360CrossRef PubMed PubMedCentral 21.Soscia SJ, Kirby JE, Washicosky KJ et al (2010) The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5(3):e9505CrossRef PubMed PubMedCentral 22.Aran A, Lin L, Nevsimalova S et al (2009) Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32(8):979–983PubMed PubMedCentral 23.Han F, Lin L, Li J et al (2012) TCRA, P2RY11, and CPT1B/CHKB associations in Chinese narcolepsy. Sleep Med 13(3):269–272CrossRef PubMed PubMedCentral 24.Kornum BR, Pizza F, Knudsen S, Plazzi G, Jennum P, Mignot E (2015) Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. Brain Behav Immun 49:54–58 25.Dauvilliers Y, Jaussent I, Lecendreux M et al (2014) Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: a case–control study. Brain Behav Immun 37:260–266CrossRef PubMed 26.De Strooper B, Vassar R, Golde T (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6:99–107CrossRef PubMed PubMedCentral 27.Honda M, Arai T, Fukazawa M et al (2009) Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy. Neurology 73:511–517CrossRef PubMed PubMedCentral 28.Economou NT, Manconi M, Ghika J, Raimondi M, Bassetti CL (2012) Development of Parkinson and Alzheimer diseases in two cases of narcolepsy-cataplexy. Eur Neurol 67(1):48–50CrossRef PubMed
作者单位:Claudio Liguori (1) Fabio Placidi (1) Francesca Izzi (1) Marzia Nuccetelli (2) Sergio Bernardini (2) Maria Giovanna Sarpa (1) Fabrizio Cum (1) Maria Grazia Marciani (3) Nicola Biagio Mercuri (1) (4) Andrea Romigi (1) (5)
1. Department of Systems Medicine, Neurophysiopathology Unit, Sleep Medicine Centre, University of Rome ‘Tor Vergata’, Viale Oxford 81, 00133, Rome, Italy 2. Clinical Biochemistry and Molecular Biology, University of Rome ‘Tor Vergata’, Rome, Italy 3. Department of Systems Medicine, Neurology Unit, University of Rome ‘Tor Vergata’, Rome, Italy 4. Fondazione Santa Lucia IRCCS, Rome, Italy 5. IRCCS Neuromed, Via Atinense 18, 86077, Pozzilli, IS, Italy